Showing results (411-420 of 586) with videos related to
Sort By:
Pageof 59
European Journal of Heart Failure|January 27, 2015
Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HFAdam D DeVore, Vic Hasselblad, Robert J Mentz, et al.The American Journal of Cardiology|November 15, 2011
Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysisRajendra H Mehta, Amanda S Stebbins, Renato D Lopes, et al.Journal of the American College of Cardiology|February 21, 2004
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trialHitinder S Gurm, A Michael Lincoff, David Lee, et al.American Heart Journal|February 9, 2002
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network TrialKenneth W Mahaffey, Matthew T Roe, Christopher K Dyke, et al.American Heart Journal|August 1, 2006
The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experienceShaun G Goodman, Yuling Fu, Anatoly Langer, et al.American Heart Journal|July 11, 2006
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothRajesh Janardhanan, Satish Kenchaiah, Eric J Velazquez, et al.American Journal of Translational Research|September 1, 2012
The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health recordsJessica D Tenenbaum, Victoria Christian, Melissa A Cornish, et al.European Heart Journal|December 4, 2003
International variation in the use of evidence-based medicines for acute coronary syndromesJudith M Kramer, L Kristin Newby, Wei Ching Chang, et al.American Heart Journal|July 6, 2010
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)Faisal Shamshad, Satish Kenchaiah, Peter V Finn, et al.Lancet (London, England)|December 24, 2013
Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysisThomas Yates, Steven M Haffner, Phillip J Schulte, et al.Pageof 59